CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before

Published:2020-11-21 Issue:3 Volume:193 Page:449-465
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br. J. Haematol.

Author:

Ghilardi Guido¹²^ORCID,Braendstrup Peter³,Chong Elise A.¹²⁴,Schuster Stephen J.¹²⁴^ORCID,Svoboda Jakub¹²⁴,Ruella Marco¹²⁴^ORCID

Affiliation:

1. Center for Cellular Immunotherapies Perelman School of Medicine at the University of Pennsylvania Philadelphia PAUSA

2. Division of Hematology‐Oncology Department of Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia PA USA

3. Department of Hematology Zealand University Hospital Roskilde Denmark

4. Abramson Cancer Center University of Pennsylvania Philadelphia PA USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17191

Reference163 articles.

1. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

2. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

3. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

4. Relapsed/Refractory Diffuse Large B-Cell Lymphoma

5. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD5 deletion enhances the antitumor activity of adoptive T cell therapies;Science Immunology;2024-07-19

2. The BTLA–HVEM axis restricts CAR T cell efficacy in cancer;Nature Immunology;2024-06

3. Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders;Biomedicines;2024-04-29

4. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel;Journal of Hematology & Oncology;2024-04-22

5. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma;NEJM Evidence;2024-03-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3